Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan
The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple ...
Pharmaceutical Technology4d
Orphan drugs: How to avoid costly stock losses in Europe
With orphan drugs typically being high value, the potential risk of stock losses should be a top concern for biotechs looking ...
Pharmaceutical Technology4d
Realising the opportunities for growth in the European orphan drug market
The European orphan drug market is growing and is already comparable in size and scope to the US market. The European Union ...
ENCell’s EN001 Receives Orphan Drug Designation from the U.S. FDA for Charcot-Marie-Tooth Disease
EN001, ENCell’s therapy under development for the treatment of Charcot-Marie-Tooth (CMT) disease, has been granted Orphan ...
Targeted Oncology2d
FDA Grants Rhenium Obisbemeda Orphan Drug Status for LM in Lung Cancer
The FDA granted orphan drug status to rhenium-186 obisbemeda for treating leptomeningeal metastases in lung cancer.
Contract Pharma3d
ENCell’s EN001 Granted Orphan Drug Designation by FDA
ENCell’s investigational drug EN001 has been granted Orphan Drug Designation by the FDA for the treatment of ...
Plus Therapeutics soars on FDA Orphan Drug Designation for lung cancer treatment
Plus Therapeutics (PSTV) soars with FDA's Orphan Drug Designation for Rhenium Obisbemeda, targeting rare leptomeningeal metastases.
Targeted Oncology4d
FDA Grants Bexmarilimab Orphan Drug Designation for MDS
The investigational immunotherapy bexmarilimab has been granted orphan drug designation from the FDA for patients with ...
DiagnaMed Granted FDA Orphan Drug Designation for Molecular Hydrogen to Treat Amyotrophic Lateral Sclerosis
Detailed price information for Diagnamed Holdings Corp. (DMED-CN) from The Globe and Mail including charting and trades.
Medical Dialogues1d
BDR Pharmaceutical Gets CDSCO Panel Nod To Manufacture Market anticancer drug Tucatinib Tablets
Tucatinib inhibits the tyrosine kinase enzyme of the HER-2 gene. Mutations of tyrosine kinase in the HER-2 gene lead to ...
Fierce Biotech14d
5 Market Access Mistakes That Can Derail Your EU Orphan Drug Launch
| Avoid common pitfalls in EU orphan drug market access—learn how local expertise can help navigate pricing, reimbursement, ...